How to balance the "potential" and "tumorigenic risk" in stem cell therapy is one of the core challenges in this field.

iPSC can be treated with an ideal combination of growth factors and culture conditions to differentiate into specified cell types.

Scientists have found that a class of omnipotent stem cells, through proliferation, differentiation, renewal and replication to produce new, healthy organs and tissues, thus extending the life span of human beings.

At present, the main methods of cell therapy are divided into two categories: immune cell therapy and stem cell therapy.

By the end of April (the first quarter of 2024), seven new drugs IND for mesenchymal stem cells (excluding hematopoietic stem cells) have been added in China, which have been approved by the Drug Evaluation Center (NMPA) of the State Drug Administration.

Recently, IQVIA, a global company in the field of life sciences, released a research report on the current status and future trends of cell and gene therapy.

From January to April 2024, a total of 5 CGT therapies were approved and put on the market worldwide, including 3 cell therapies and 2 gene therapies.

Recently, the Guangdong Provincial Health Commission took the lead in establishing China's first provincial stem cell clinical research quality control center in China.